ArticleNature2022
African clinical trial denied access to key COVID drug Paxlovid.
Article in Nature, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Efficacy and Safety of Molnupiravir Treatment for COVID-19: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.International journal of antimicrobial agents · 2023Pooled it
- Assessing the burden of COVID-19 in developing countries: systematic review, meta-analysis and public policy implications.BMJ global health · 2022Pooled it
- Therapeutic effect of N-acetylcysteine in severe or critical coronavirus disease 2019 pneumonia: A retrospective cohort study.The Journal of international medical research · 2026Article
- Advances in the effectiveness and safety of azvudine treatment: a comprehensive review.Frontiers in pharmacology · 2025Review
- Article
- A novel class of broad-spectrum active-site-directed 3C-like protease inhibitors with nanomolar antiviral activity against highly immune-evasive SARS-CoV-2 Omicron subvariants.Emerging microbes & infections · 2023Article
- Efficacy and safety of azvudine in patients with COVID-19: A systematic review and meta-analysis.Heliyon · 2023Review
- Resistance to nirmatrelvir due to mutations in the Mpro in the subvariants of SARS-CoV-2 Omicron: Another concern?Molecular therapy. Nucleic acids · 2023Article
- mRNA-based COVID-19 booster vaccination is highly effective and cost-effective in Australia.Vaccine · 2023Article
- Funding and COVID-19 research in Africa: two years on, are the research needs of Africa being met?Open research Africa · 2023Article
- Voluntariness or legal obligation? An ethical analysis of two instruments for fairer global access to COVID-19 vaccines.Frontiers in public health · 2023Article
- Nasal irrigation efficiently attenuates SARS-CoV-2 Omicron infection, transmission and lung injury in the Syrian hamster model.iScience · 2022Article
- Strengthening vaccines and medicines manufacturing capabilities in Africa: challenges and perspectives.EMBO molecular medicine · 2022Article
Corrections and comments
- Comment on
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
35379975What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.